NULOJIX (belatacept): Further extension of the temporary restriction in supply up until 3Q 2022.

Summary:

• The temporary restriction in supply of Nulojix (belatacept) will be further extended until 3Q 2022. 
• Due to the restriction in supply, Nulojix can only be prescribed to new patients if the following two criteria are met:
  • Nulojix is the best treatment option for the patient 
  • BMS has confirmed that supplies are adequate for new and existing patients. 
• Before initiating Nulojix treatment in new patients, BMS Medical Information should be contacted to confirm that adequate supplies are available (see contact details below (by country)).